{"gene":"APOC2","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":2023,"finding":"APOC2's C-terminal α-helix binds to regions of LPL surrounding the catalytic pocket, overlapping with the ANGPTL4 binding site. Unlike ANGPTL4, APOC2 binding increases the thermal stability of LPL and stabilizes the lid-anchoring structures, providing a mechanism for LPL activation versus ANGPTL4-mediated inhibition.","method":"Hydrogen-deuterium exchange mass spectrometry (HDX-MS) mapping of APOC2 and ANGPTL4 binding sites on LPL with functional thermal stability assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — HDX-MS with direct binding site mapping and functional validation (thermal stability), multiple orthogonal comparisons in a single rigorous study","pmids":["37094117"],"is_preprint":false},{"year":2017,"finding":"The APOC2 missense variant R72T reduces lipid binding affinity of the apoC-II peptide (by molecular modeling) and results in complete absence of functional apoC-II activity in patient plasma, confirmed by in vitro studies of patient plasma lacking apoC-II-mediated LPL activation.","method":"Molecular modeling of R72T variant; in vitro functional assay of patient plasma for apoC-II activity; immunoblot/quantitative protein assay","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro functional assay of patient plasma combined with molecular modeling; single lab, two complementary methods","pmids":["28201738"],"is_preprint":false},{"year":2020,"finding":"ApoC2 is an obligatory activator of lipoprotein lipase-mediated hydrolysis of triglyceride-rich lipoproteins in vivo; CRISPR/Cas9 deletion of Apoc2 in golden Syrian hamsters causes severe hypertriglyceridemia that is fully corrected by AAV-mediated human ApoC2 restoration, demonstrating that ApoC2 is essential for plasma triglyceride clearance.","method":"CRISPR/Cas9 knockout in hamster; AAV-hApoC2 rescue; lipid profiling; medium-chain triglyceride diet intervention","journal":"Metabolism: clinical and experimental","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo loss-of-function with genetic rescue (AAV), multiple interventional controls, and quantitative lipid phenotyping","pmids":["32562799"],"is_preprint":false},{"year":2017,"finding":"Apoc2 knockout zebrafish show deficient plasma cholesterol esterification: hepatic expression of lcat (lecithin-cholesterol acyltransferase) and apolipoprotein A-I are dramatically decreased, and this LCAT activity deficit is also observed in human FCS patients, linking APOC2/LPL-mediated triglyceride metabolism to plasma cholesterol esterification.","method":"apoc2 knockout zebrafish model; in situ hybridization; qPCR for lcat and apoA-I; plasma FC/CE ratio measurement; LCAT activity assay in human FCS patient plasma","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — zebrafish KO model with multiple orthogonal methods (ISH, qPCR, enzymatic assay) validated in human patient samples","pmids":["28107429"],"is_preprint":false},{"year":2020,"finding":"AAV-mediated delivery of human ApoC2 (AAV-hApoC2) to ApoC2-deficient hamsters rescues neonatal lethality and reverses severe hypertriglyceridemia long-term, demonstrating ApoC2 as a sufficient activator of lipoprotein lipase-mediated triglyceride clearance in vivo.","method":"AAV-hApoC2 administration via jugular or orbital vein in neonatal and adult ApoC2-deficient hamsters; plasma triglyceride measurement; long-term safety assessment","journal":"Molecular therapy. Methods & clinical development","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo gene therapy rescue in established KO model with quantitative lipid outcomes and long-term follow-up; replicates findings from companion paper (PMID:32562799)","pmids":["32802915"],"is_preprint":false},{"year":2025,"finding":"FXR activation in beige adipocytes upregulates ApoC2 expression, and ApoC2 overexpression in preadipocytes and beige adipocytes increases expression of UCP1 and PGC1α, placing ApoC2 downstream of FXR in a pathway promoting browning of white adipose tissue.","method":"FXR agonist (farnesol) treatment in beige adipocytes and cold-exposed mice; FXR knockdown; ApoC2 overexpression in preadipocytes and beige adipocytes; Western blot and RT-qPCR for UCP1, PGC1α, PRDM16, ApoC2","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function (FXR KD) and gain-of-function (ApoC2 OE) with defined molecular readouts, single lab","pmids":["39798876"],"is_preprint":false},{"year":2020,"finding":"miR-1275 directly targets the 3' UTR of ApoC2 and suppresses its expression in macrophages; ApoC2 knockdown in THP-1-derived macrophages inhibits cellular uptake of ox-LDL and suppresses macrophage foam cell formation, placing ApoC2 as a positive regulator of foam cell formation downstream of miR-1275.","method":"Dual-luciferase reporter assay; miR-1275 overexpression; ApoC2 siRNA knockdown in THP-1-derived macrophages; ox-LDL uptake assay; RT-qPCR and protein quantification","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase reporter validates direct targeting, KD phenotype reproduced by miRNA OE, single lab with two orthogonal methods","pmids":["31935511"],"is_preprint":false},{"year":2020,"finding":"miR-4510 directly targets APOC2 (validated by luciferase reporter assay); APOC2 knockdown in GIST cells suppresses cell proliferation, migration, and invasion and reduces phosphorylation of AKT and ERK1/2, as well as MMP2 and MMP9 expression, indicating APOC2 promotes GIST progression via AKT/ERK signaling.","method":"Luciferase reporter assay; APOC2 siRNA knockdown in GIST cells; cell proliferation, migration and invasion assays; Western blot for p-AKT, p-ERK1/2, MMP2, MMP9","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct target validation by luciferase assay plus mechanistic pathway readout by KD, single lab","pmids":["31975384"],"is_preprint":false},{"year":2025,"finding":"APOC2 knockdown in clear cell renal cell carcinoma (ccRCC) cells reduces phosphorylation of JAK1/2 and STAT3 without affecting total protein levels; rescue with the STAT3 agonist Colivelin partially reverses decreased cell viability and increased apoptosis caused by APOC2 knockdown, supporting that APOC2 promotes ccRCC cell proliferation via JAK-STAT signaling.","method":"APOC2 siRNA knockdown in ccRCC cell lines; Western blot for p-JAK1, p-JAK2, p-STAT3; STAT3 agonist (Colivelin) rescue experiments; cell viability and apoptosis assays","journal":"Current issues in molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD with pathway-level molecular readout and pharmacological rescue, single lab","pmids":["41296440"],"is_preprint":false},{"year":2013,"finding":"In a patient with apoC-II deficiency and no rare coding variant in APOC2, transcription of apoC-II mRNA was decreased in monocyte/macrophage culture and transcriptional activity of an APOC2 minigene reporter construct was reduced, demonstrating that non-coding regulatory regions can control APOC2 transcription and that other genes can regulate apoC-II levels.","method":"Monocyte/macrophage culture; RT-PCR for apoC-II mRNA; minigene reporter construct transcriptional activity assay; Sanger sequencing of APOC2 coding and regulatory regions","journal":"Journal of atherosclerosis and thrombosis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — minigene reporter assay directly tests promoter/regulatory activity; complemented by cell-based mRNA analysis; single lab","pmids":["23470567"],"is_preprint":false}],"current_model":"APOC2 encodes apolipoprotein C-II, whose C-terminal α-helix binds directly to the catalytic pocket region of lipoprotein lipase (LPL), stabilizing LPL's lid-anchoring structures and increasing its thermal stability to activate triglyceride hydrolysis from triglyceride-rich lipoproteins; loss of APOC2 causes severe hypertriglyceridemia (demonstrated in hamster KO and zebrafish KO models) and secondarily impairs plasma cholesterol esterification by reducing hepatic LCAT expression; APOC2 expression is regulated transcriptionally by FXR (placing it in a browning/thermogenesis pathway in adipose tissue) and post-transcriptionally by miRNAs (miR-1275, miR-4510, miR-107); in macrophages and tumor cells, APOC2 promotes downstream AKT/ERK and JAK-STAT signaling to drive foam cell formation and cancer cell proliferation respectively."},"narrative":{"mechanistic_narrative":"APOC2 encodes apolipoprotein C-II, an obligatory activator of lipoprotein lipase (LPL)-mediated hydrolysis of triglyceride-rich lipoproteins and an essential determinant of plasma triglyceride clearance [PMID:32562799]. Its C-terminal α-helix binds directly to regions of LPL surrounding the catalytic pocket—overlapping the inhibitory ANGPTL4 site—but, unlike ANGPTL4, increases LPL thermal stability and stabilizes the lid-anchoring structures, explaining how APOC2 activates rather than inhibits the enzyme [PMID:37094117]. In vivo loss-of-function confirms this role: CRISPR deletion of Apoc2 in hamsters causes severe hypertriglyceridemia and neonatal lethality that is fully reversed by AAV-delivered human APOC2, establishing APOC2 as both necessary and sufficient for triglyceride clearance [PMID:32562799, PMID:32802915]. Loss of APOC2 secondarily impairs plasma cholesterol esterification through reduced hepatic LCAT and apolipoprotein A-I expression, linking the LPL-triglyceride axis to cholesterol handling [PMID:28107429]. A missense variant (R72T) that reduces lipid binding abolishes apoC-II activity in patient plasma, and non-coding regulatory defects can likewise lower apoC-II levels, together accounting for inherited apoC-II deficiency and familial chylomicronemia [PMID:28201738, PMID:23470567]. Beyond lipid metabolism, APOC2 expression is induced downstream of FXR in beige adipocytes where it promotes thermogenic gene expression [PMID:39798876], is repressed post-transcriptionally by miRNAs targeting its 3' UTR [PMID:31935511, PMID:31975384], and acts as a positive regulator of macrophage foam cell formation [PMID:31935511] and of tumor cell proliferation via AKT/ERK and JAK-STAT signaling [PMID:31975384, PMID:41296440].","teleology":[{"year":2013,"claim":"Established that APOC2 levels can be controlled at the transcriptional/regulatory level, not only by coding mutations, explaining apoC-II deficiency in patients lacking rare coding variants.","evidence":"Monocyte/macrophage mRNA analysis and APOC2 minigene reporter assay in a deficient patient","pmids":["23470567"],"confidence":"Medium","gaps":["Specific non-coding regulatory element and trans-acting regulator not identified","Single patient/single lab"]},{"year":2017,"claim":"Showed how a coding variant abolishes function, connecting reduced lipid binding to loss of LPL activation in patient plasma.","evidence":"Molecular modeling of R72T plus in vitro apoC-II activity assay of patient plasma","pmids":["28201738"],"confidence":"Medium","gaps":["Lipid-binding deficit inferred from modeling, not direct structural measurement","Not tested in a controlled in vivo system"]},{"year":2017,"claim":"Revealed a secondary consequence of APOC2 loss beyond triglyceride accumulation, linking the LPL-triglyceride axis to plasma cholesterol esterification via hepatic LCAT.","evidence":"apoc2 knockout zebrafish with ISH/qPCR for lcat and apoA-I, plasma FC/CE ratio, and LCAT activity in human FCS plasma","pmids":["28107429"],"confidence":"High","gaps":["Mechanism by which APOC2/LPL loss represses hepatic LCAT expression unresolved","Direct versus indirect regulation of apoA-I not distinguished"]},{"year":2020,"claim":"Demonstrated genetically that APOC2 is both necessary and sufficient for plasma triglyceride clearance in a mammalian model.","evidence":"CRISPR/Cas9 Apoc2 knockout hamster with AAV-hApoC2 rescue and lipid phenotyping","pmids":["32562799","32802915"],"confidence":"High","gaps":["Quantitative contribution of APOC2 relative to other LPL regulators in vivo not dissected","Tissue-specific requirements not addressed"]},{"year":2020,"claim":"Extended APOC2 biology into non-lipoprotein roles by placing it as a miRNA-controlled positive regulator of macrophage foam cell formation and of tumor cell signaling.","evidence":"Luciferase reporter validation of miR-1275/miR-4510 targeting plus APOC2 knockdown with ox-LDL uptake and AKT/ERK readouts in macrophages and GIST cells","pmids":["31935511","31975384"],"confidence":"Medium","gaps":["Whether intracellular/autocrine APOC2 signals independently of its extracellular LPL-cofactor role unclear","Direct receptor or effector linking APOC2 to AKT/ERK not identified"]},{"year":2023,"claim":"Resolved the molecular basis of LPL activation versus inhibition, showing APOC2 and ANGPTL4 bind overlapping LPL sites but exert opposite effects on enzyme stability.","evidence":"HDX-MS binding-site mapping of APOC2 and ANGPTL4 on LPL with thermal stability assays","pmids":["37094117"],"confidence":"High","gaps":["No high-resolution co-structure of the APOC2–LPL complex","How lid stabilization translates to increased catalysis kinetically not defined"]},{"year":2025,"claim":"Connected APOC2 to thermogenic adipose biology by placing it downstream of FXR and upstream of browning markers.","evidence":"FXR agonist/knockdown and APOC2 overexpression in beige adipocytes with UCP1/PGC1α readouts","pmids":["39798876"],"confidence":"Medium","gaps":["Mechanism by which APOC2 induces UCP1/PGC1α unknown","Single lab, in vivo relevance to whole-body thermogenesis not established"]},{"year":2025,"claim":"Implicated APOC2 in cancer cell survival through JAK-STAT signaling in renal carcinoma.","evidence":"APOC2 knockdown in ccRCC cells with p-JAK1/2/STAT3 readout and STAT3 agonist rescue","pmids":["41296440"],"confidence":"Medium","gaps":["Direct link between APOC2 and JAK activation not defined","Whether effect is cell-intrinsic or secretion-dependent unresolved"]},{"year":null,"claim":"How APOC2's canonical extracellular lipase-cofactor function mechanistically relates to its reported intracellular/signaling roles in macrophages, adipocytes, and tumor cells remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying mechanism links LPL activation to AKT/ERK and JAK-STAT signaling","No structural model of the APOC2–LPL complex","Receptors mediating non-lipolytic APOC2 effects unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,2,4]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,2,3]}],"complexes":[],"partners":["LPL"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P02655","full_name":"Apolipoprotein C-II","aliases":["Apolipoprotein C2"],"length_aa":101,"mass_kda":11.3,"function":"Component of chylomicrons, very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) in plasma. Plays an important role in lipoprotein metabolism as an activator of lipoprotein lipase. Both proapolipoprotein C-II and apolipoprotein C-II can activate lipoprotein lipase. In normolipidemic individuals, it is mainly distributed in the HDL, whereas in hypertriglyceridemic individuals, predominantly found in the VLDL and LDL","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P02655/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APOC2","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APOC2","total_profiled":1310},"omim":[{"mim_id":"615947","title":"HYPERLIPOPROTEINEMIA, TYPE ID","url":"https://www.omim.org/entry/615947"},{"mim_id":"613230","title":"PEPTIDASE D; PEPD","url":"https://www.omim.org/entry/613230"},{"mim_id":"612773","title":"BASAL CELL ADHESION MOLECULE; BCAM","url":"https://www.omim.org/entry/612773"},{"mim_id":"612757","title":"GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED HIGH DENSITY LIPOPROTEIN-BINDING PROTEIN 1; GPIHBP1","url":"https://www.omim.org/entry/612757"},{"mim_id":"611998","title":"cAMP RESPONSE ELEMENT-BINDING PROTEIN 3-LIKE 3; CREB3L3","url":"https://www.omim.org/entry/611998"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":8987.5}],"url":"https://www.proteinatlas.org/search/APOC2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P02655","domains":[{"cath_id":"1.20.5","chopping":"64-89","consensus_level":"medium","plddt":61.6608,"start":64,"end":89}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P02655","model_url":"https://alphafold.ebi.ac.uk/files/AF-P02655-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P02655-F1-predicted_aligned_error_v6.png","plddt_mean":65.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APOC2","jax_strain_url":"https://www.jax.org/strain/search?query=APOC2"},"sequence":{"accession":"P02655","fasta_url":"https://rest.uniprot.org/uniprotkb/P02655.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P02655/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P02655"}},"corpus_meta":[{"pmid":"22239554","id":"PMC_22239554","title":"Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia.","date":"2012","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22239554","citation_count":204,"is_preprint":false},{"pmid":"8062276","id":"PMC_8062276","title":"The putative glioma tumor suppressor gene on chromosome 19q maps between APOC2 and HRC.","date":"1994","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8062276","citation_count":81,"is_preprint":false},{"pmid":"2892779","id":"PMC_2892779","title":"Apolipoprotein gene cluster on chromosome 19. Definite localization of the APOC2 gene and the polymorphic Hpa I site associated with type III hyperlipoproteinemia.","date":"1988","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2892779","citation_count":68,"is_preprint":false},{"pmid":"29371683","id":"PMC_29371683","title":"DNA methylation of TOMM40-APOE-APOC2 in Alzheimer's disease.","date":"2018","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29371683","citation_count":66,"is_preprint":false},{"pmid":"35820705","id":"PMC_35820705","title":"ScRNA-seq expression of IFI27 and APOC2 identifies four alveolar macrophage superclusters in healthy BALF.","date":"2022","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/35820705","citation_count":59,"is_preprint":false},{"pmid":"28201738","id":"PMC_28201738","title":"A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis.","date":"2017","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28201738","citation_count":34,"is_preprint":false},{"pmid":"32562799","id":"PMC_32562799","title":"ApoC2 deficiency elicits severe hypertriglyceridemia and spontaneous atherosclerosis: A rodent model rescued from neonatal death.","date":"2020","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/32562799","citation_count":30,"is_preprint":false},{"pmid":"1763885","id":"PMC_1763885","title":"The human chromosome 19 linkage group FUT1 (H), FUT2 (SE), LE, LU, PEPD, C3, APOC2, D19S7 and D19S9.","date":"1991","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1763885","citation_count":29,"is_preprint":false},{"pmid":"17192963","id":"PMC_17192963","title":"Preimplantation genetic diagnosis for myotonic dystrophy type 1: detection of crossover between the gene and the linked marker APOC2.","date":"2007","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/17192963","citation_count":23,"is_preprint":false},{"pmid":"37094117","id":"PMC_37094117","title":"Inverse effects of APOC2 and ANGPTL4 on the conformational dynamics of lid-anchoring structures in lipoprotein lipase.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37094117","citation_count":21,"is_preprint":false},{"pmid":"26772541","id":"PMC_26772541","title":"A novel APOC2 gene mutation identified in a Chinese patient with severe hypertriglyceridemia and recurrent pancreatitis.","date":"2016","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/26772541","citation_count":21,"is_preprint":false},{"pmid":"2907851","id":"PMC_2907851","title":"The chromosome 19 linkage group LDLR, C3, LW, APOC2, LU, SE in man.","date":"1988","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2907851","citation_count":20,"is_preprint":false},{"pmid":"2591962","id":"PMC_2591962","title":"Recombination events that locate myotonic dystrophy distal to APOC2 on 19q.","date":"1989","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/2591962","citation_count":19,"is_preprint":false},{"pmid":"25172036","id":"PMC_25172036","title":"Apolipoprotein C-II Tuzla: a novel large deletion in APOC2 caused by Alu-Alu homologous recombination in an infant with apolipoprotein C-II deficiency.","date":"2014","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25172036","citation_count":16,"is_preprint":false},{"pmid":"31975384","id":"PMC_31975384","title":"miR-4510 acts as a tumor suppressor in gastrointestinal stromal tumor by targeting APOC2.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31975384","citation_count":14,"is_preprint":false},{"pmid":"8471544","id":"PMC_8471544","title":"Genetic variation of microsatellite markers D1S117, D6S89, D11S35, APOC2, and D21S168 in the Spanish population.","date":"1993","source":"International journal of legal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8471544","citation_count":13,"is_preprint":false},{"pmid":"32802915","id":"PMC_32802915","title":"AAV-Mediated ApoC2 Gene Therapy: Reversal of Severe Hypertriglyceridemia and Rescue of Neonatal Death in ApoC2-Deficient Hamsters.","date":"2020","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/32802915","citation_count":12,"is_preprint":false},{"pmid":"28107429","id":"PMC_28107429","title":"Deficient Cholesterol Esterification in Plasma of apoc2 Knockout Zebrafish and Familial Chylomicronemia Patients.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28107429","citation_count":10,"is_preprint":false},{"pmid":"8001915","id":"PMC_8001915","title":"Genetic studies on the Senegal population. II. Polymorphisms of the plasma proteins F13A, F13B, ORM1, AHSG, C6, C7, and APOC2.","date":"1994","source":"Human biology","url":"https://pubmed.ncbi.nlm.nih.gov/8001915","citation_count":10,"is_preprint":false},{"pmid":"3198115","id":"PMC_3198115","title":"Segregation of linked probes to myotonic dystrophy in a family demonstrating that 152 and APOC2 are on the same side of DM on 19q.","date":"1988","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/3198115","citation_count":8,"is_preprint":false},{"pmid":"31935511","id":"PMC_31935511","title":"Blood miR-1275 is associated with risk of ischemic stroke and inhibits macrophage foam cell formation by targeting ApoC2 gene.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/31935511","citation_count":7,"is_preprint":false},{"pmid":"36690263","id":"PMC_36690263","title":"Comprehensive in-silico analysis of deleterious SNPs in APOC2 and APOA5 and their differential expression in cancer and cardiovascular diseases conditions.","date":"2023","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/36690263","citation_count":6,"is_preprint":false},{"pmid":"36011378","id":"PMC_36011378","title":"MiR-107 Regulates Adipocyte Differentiation and Adipogenesis by Targeting Apolipoprotein C-2 (APOC2) in Bovine.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36011378","citation_count":6,"is_preprint":false},{"pmid":"38938447","id":"PMC_38938447","title":"Pancreatitis as a Main Consequence of APOC2-Related Hypertriglyceridemia: The Role of Nonsense and Frameshift Variants.","date":"2024","source":"International journal of genomics","url":"https://pubmed.ncbi.nlm.nih.gov/38938447","citation_count":6,"is_preprint":false},{"pmid":"32280258","id":"PMC_32280258","title":"A Novel APOC2 Mutation in a Colombian Patient with Recurrent Hypertriglyceridemic Pancreatitis.","date":"2020","source":"The application of clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32280258","citation_count":6,"is_preprint":false},{"pmid":"33129550","id":"PMC_33129550","title":"Sequence analysis of the coding regions of the apolipoprotein C2 (APOC2) gene in Miniature Schnauzers with idiopathic hypertriglyceridemia.","date":"2020","source":"Veterinary journal (London, England : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/33129550","citation_count":6,"is_preprint":false},{"pmid":"23470567","id":"PMC_23470567","title":"Apolipoprotein C-II deficiency with no rare variant in the APOC2 gene.","date":"2013","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/23470567","citation_count":6,"is_preprint":false},{"pmid":"32292609","id":"PMC_32292609","title":"Experimental Therapeutics for Challenging Clinical Care of a Patient with an Extremely Rare Homozygous APOC2 Mutation.","date":"2020","source":"Case reports in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32292609","citation_count":6,"is_preprint":false},{"pmid":"30307897","id":"PMC_30307897","title":"Severe hyperchylomicronemia in two infants with novel APOC2 gene mutation.","date":"2018","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/30307897","citation_count":5,"is_preprint":false},{"pmid":"3047535","id":"PMC_3047535","title":"Presymptomatic testing for myotonic dystrophy by means of the linked DNA marker APOC2.","date":"1988","source":"The Medical journal of Australia","url":"https://pubmed.ncbi.nlm.nih.gov/3047535","citation_count":5,"is_preprint":false},{"pmid":"39798876","id":"PMC_39798876","title":"FXR-ApoC2 pathway activates UCP1-mediated thermogenesis by promoting the browning of white adipose tissues.","date":"2025","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39798876","citation_count":4,"is_preprint":false},{"pmid":"40983153","id":"PMC_40983153","title":"High-throughput screening reveals paeoniflorin's efficacy against Apoc2-deficient hypertriglyceridemia via HNF4A/PPARA/LDLR.","date":"2025","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40983153","citation_count":2,"is_preprint":false},{"pmid":"20940006","id":"PMC_20940006","title":"Identification of mutations in the lipoprotein lipase (LPL) and apolipoprotein C-II (APOC2) genes using denaturing high performance liquid chromatography (DHPLC).","date":"2010","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20940006","citation_count":2,"is_preprint":false},{"pmid":"41296440","id":"PMC_41296440","title":"APOC2 Promotes Clear Cell Renal Cell Carcinoma Progression via Activation of the JAK-STAT Signaling Pathway.","date":"2025","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/41296440","citation_count":1,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.08.01.667173","title":"Nanoparticle-enabled plasma proteomics of a mouse atherosclerosis model","date":"2025-08-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.01.667173","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.01.662592","title":"Haplotype-Resolved DNA Methylation at the  <i>APOE</i>  Locus identifies Allele-Specific Epigenetic Signatures Relevant to Alzheimer’s Disease Risk","date":"2025-07-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.01.662592","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.24.655950","title":"Robust Serum Proteomic Signatures of APOE2","date":"2025-05-29","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.24.655950","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.10.25323519","title":"A Quantitative Trait Locus for Reduced Microglial<i>APOE</i>Expression Associates with Reduced Cerebral Amyloid Angiopathy","date":"2025-03-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.10.25323519","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":21385,"output_tokens":2855,"usd":0.05349,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10167,"output_tokens":2906,"usd":0.061742,"stage2_stop_reason":"end_turn"},"total_usd":0.115232,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2023,\n      \"finding\": \"APOC2's C-terminal α-helix binds to regions of LPL surrounding the catalytic pocket, overlapping with the ANGPTL4 binding site. Unlike ANGPTL4, APOC2 binding increases the thermal stability of LPL and stabilizes the lid-anchoring structures, providing a mechanism for LPL activation versus ANGPTL4-mediated inhibition.\",\n      \"method\": \"Hydrogen-deuterium exchange mass spectrometry (HDX-MS) mapping of APOC2 and ANGPTL4 binding sites on LPL with functional thermal stability assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — HDX-MS with direct binding site mapping and functional validation (thermal stability), multiple orthogonal comparisons in a single rigorous study\",\n      \"pmids\": [\"37094117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The APOC2 missense variant R72T reduces lipid binding affinity of the apoC-II peptide (by molecular modeling) and results in complete absence of functional apoC-II activity in patient plasma, confirmed by in vitro studies of patient plasma lacking apoC-II-mediated LPL activation.\",\n      \"method\": \"Molecular modeling of R72T variant; in vitro functional assay of patient plasma for apoC-II activity; immunoblot/quantitative protein assay\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro functional assay of patient plasma combined with molecular modeling; single lab, two complementary methods\",\n      \"pmids\": [\"28201738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ApoC2 is an obligatory activator of lipoprotein lipase-mediated hydrolysis of triglyceride-rich lipoproteins in vivo; CRISPR/Cas9 deletion of Apoc2 in golden Syrian hamsters causes severe hypertriglyceridemia that is fully corrected by AAV-mediated human ApoC2 restoration, demonstrating that ApoC2 is essential for plasma triglyceride clearance.\",\n      \"method\": \"CRISPR/Cas9 knockout in hamster; AAV-hApoC2 rescue; lipid profiling; medium-chain triglyceride diet intervention\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo loss-of-function with genetic rescue (AAV), multiple interventional controls, and quantitative lipid phenotyping\",\n      \"pmids\": [\"32562799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Apoc2 knockout zebrafish show deficient plasma cholesterol esterification: hepatic expression of lcat (lecithin-cholesterol acyltransferase) and apolipoprotein A-I are dramatically decreased, and this LCAT activity deficit is also observed in human FCS patients, linking APOC2/LPL-mediated triglyceride metabolism to plasma cholesterol esterification.\",\n      \"method\": \"apoc2 knockout zebrafish model; in situ hybridization; qPCR for lcat and apoA-I; plasma FC/CE ratio measurement; LCAT activity assay in human FCS patient plasma\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — zebrafish KO model with multiple orthogonal methods (ISH, qPCR, enzymatic assay) validated in human patient samples\",\n      \"pmids\": [\"28107429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"AAV-mediated delivery of human ApoC2 (AAV-hApoC2) to ApoC2-deficient hamsters rescues neonatal lethality and reverses severe hypertriglyceridemia long-term, demonstrating ApoC2 as a sufficient activator of lipoprotein lipase-mediated triglyceride clearance in vivo.\",\n      \"method\": \"AAV-hApoC2 administration via jugular or orbital vein in neonatal and adult ApoC2-deficient hamsters; plasma triglyceride measurement; long-term safety assessment\",\n      \"journal\": \"Molecular therapy. Methods & clinical development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo gene therapy rescue in established KO model with quantitative lipid outcomes and long-term follow-up; replicates findings from companion paper (PMID:32562799)\",\n      \"pmids\": [\"32802915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FXR activation in beige adipocytes upregulates ApoC2 expression, and ApoC2 overexpression in preadipocytes and beige adipocytes increases expression of UCP1 and PGC1α, placing ApoC2 downstream of FXR in a pathway promoting browning of white adipose tissue.\",\n      \"method\": \"FXR agonist (farnesol) treatment in beige adipocytes and cold-exposed mice; FXR knockdown; ApoC2 overexpression in preadipocytes and beige adipocytes; Western blot and RT-qPCR for UCP1, PGC1α, PRDM16, ApoC2\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function (FXR KD) and gain-of-function (ApoC2 OE) with defined molecular readouts, single lab\",\n      \"pmids\": [\"39798876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-1275 directly targets the 3' UTR of ApoC2 and suppresses its expression in macrophages; ApoC2 knockdown in THP-1-derived macrophages inhibits cellular uptake of ox-LDL and suppresses macrophage foam cell formation, placing ApoC2 as a positive regulator of foam cell formation downstream of miR-1275.\",\n      \"method\": \"Dual-luciferase reporter assay; miR-1275 overexpression; ApoC2 siRNA knockdown in THP-1-derived macrophages; ox-LDL uptake assay; RT-qPCR and protein quantification\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase reporter validates direct targeting, KD phenotype reproduced by miRNA OE, single lab with two orthogonal methods\",\n      \"pmids\": [\"31935511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-4510 directly targets APOC2 (validated by luciferase reporter assay); APOC2 knockdown in GIST cells suppresses cell proliferation, migration, and invasion and reduces phosphorylation of AKT and ERK1/2, as well as MMP2 and MMP9 expression, indicating APOC2 promotes GIST progression via AKT/ERK signaling.\",\n      \"method\": \"Luciferase reporter assay; APOC2 siRNA knockdown in GIST cells; cell proliferation, migration and invasion assays; Western blot for p-AKT, p-ERK1/2, MMP2, MMP9\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct target validation by luciferase assay plus mechanistic pathway readout by KD, single lab\",\n      \"pmids\": [\"31975384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"APOC2 knockdown in clear cell renal cell carcinoma (ccRCC) cells reduces phosphorylation of JAK1/2 and STAT3 without affecting total protein levels; rescue with the STAT3 agonist Colivelin partially reverses decreased cell viability and increased apoptosis caused by APOC2 knockdown, supporting that APOC2 promotes ccRCC cell proliferation via JAK-STAT signaling.\",\n      \"method\": \"APOC2 siRNA knockdown in ccRCC cell lines; Western blot for p-JAK1, p-JAK2, p-STAT3; STAT3 agonist (Colivelin) rescue experiments; cell viability and apoptosis assays\",\n      \"journal\": \"Current issues in molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD with pathway-level molecular readout and pharmacological rescue, single lab\",\n      \"pmids\": [\"41296440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In a patient with apoC-II deficiency and no rare coding variant in APOC2, transcription of apoC-II mRNA was decreased in monocyte/macrophage culture and transcriptional activity of an APOC2 minigene reporter construct was reduced, demonstrating that non-coding regulatory regions can control APOC2 transcription and that other genes can regulate apoC-II levels.\",\n      \"method\": \"Monocyte/macrophage culture; RT-PCR for apoC-II mRNA; minigene reporter construct transcriptional activity assay; Sanger sequencing of APOC2 coding and regulatory regions\",\n      \"journal\": \"Journal of atherosclerosis and thrombosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — minigene reporter assay directly tests promoter/regulatory activity; complemented by cell-based mRNA analysis; single lab\",\n      \"pmids\": [\"23470567\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"APOC2 encodes apolipoprotein C-II, whose C-terminal α-helix binds directly to the catalytic pocket region of lipoprotein lipase (LPL), stabilizing LPL's lid-anchoring structures and increasing its thermal stability to activate triglyceride hydrolysis from triglyceride-rich lipoproteins; loss of APOC2 causes severe hypertriglyceridemia (demonstrated in hamster KO and zebrafish KO models) and secondarily impairs plasma cholesterol esterification by reducing hepatic LCAT expression; APOC2 expression is regulated transcriptionally by FXR (placing it in a browning/thermogenesis pathway in adipose tissue) and post-transcriptionally by miRNAs (miR-1275, miR-4510, miR-107); in macrophages and tumor cells, APOC2 promotes downstream AKT/ERK and JAK-STAT signaling to drive foam cell formation and cancer cell proliferation respectively.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"APOC2 encodes apolipoprotein C-II, an obligatory activator of lipoprotein lipase (LPL)-mediated hydrolysis of triglyceride-rich lipoproteins and an essential determinant of plasma triglyceride clearance [#2]. Its C-terminal \\u03b1-helix binds directly to regions of LPL surrounding the catalytic pocket\\u2014overlapping the inhibitory ANGPTL4 site\\u2014but, unlike ANGPTL4, increases LPL thermal stability and stabilizes the lid-anchoring structures, explaining how APOC2 activates rather than inhibits the enzyme [#0]. In vivo loss-of-function confirms this role: CRISPR deletion of Apoc2 in hamsters causes severe hypertriglyceridemia and neonatal lethality that is fully reversed by AAV-delivered human APOC2, establishing APOC2 as both necessary and sufficient for triglyceride clearance [#2, #4]. Loss of APOC2 secondarily impairs plasma cholesterol esterification through reduced hepatic LCAT and apolipoprotein A-I expression, linking the LPL-triglyceride axis to cholesterol handling [#3]. A missense variant (R72T) that reduces lipid binding abolishes apoC-II activity in patient plasma, and non-coding regulatory defects can likewise lower apoC-II levels, together accounting for inherited apoC-II deficiency and familial chylomicronemia [#1, #9]. Beyond lipid metabolism, APOC2 expression is induced downstream of FXR in beige adipocytes where it promotes thermogenic gene expression [#5], is repressed post-transcriptionally by miRNAs targeting its 3' UTR [#6, #7], and acts as a positive regulator of macrophage foam cell formation [#6] and of tumor cell proliferation via AKT/ERK and JAK-STAT signaling [#7, #8].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Established that APOC2 levels can be controlled at the transcriptional/regulatory level, not only by coding mutations, explaining apoC-II deficiency in patients lacking rare coding variants.\",\n      \"evidence\": \"Monocyte/macrophage mRNA analysis and APOC2 minigene reporter assay in a deficient patient\",\n      \"pmids\": [\"23470567\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific non-coding regulatory element and trans-acting regulator not identified\", \"Single patient/single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed how a coding variant abolishes function, connecting reduced lipid binding to loss of LPL activation in patient plasma.\",\n      \"evidence\": \"Molecular modeling of R72T plus in vitro apoC-II activity assay of patient plasma\",\n      \"pmids\": [\"28201738\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Lipid-binding deficit inferred from modeling, not direct structural measurement\", \"Not tested in a controlled in vivo system\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed a secondary consequence of APOC2 loss beyond triglyceride accumulation, linking the LPL-triglyceride axis to plasma cholesterol esterification via hepatic LCAT.\",\n      \"evidence\": \"apoc2 knockout zebrafish with ISH/qPCR for lcat and apoA-I, plasma FC/CE ratio, and LCAT activity in human FCS plasma\",\n      \"pmids\": [\"28107429\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which APOC2/LPL loss represses hepatic LCAT expression unresolved\", \"Direct versus indirect regulation of apoA-I not distinguished\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated genetically that APOC2 is both necessary and sufficient for plasma triglyceride clearance in a mammalian model.\",\n      \"evidence\": \"CRISPR/Cas9 Apoc2 knockout hamster with AAV-hApoC2 rescue and lipid phenotyping\",\n      \"pmids\": [\"32562799\", \"32802915\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of APOC2 relative to other LPL regulators in vivo not dissected\", \"Tissue-specific requirements not addressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extended APOC2 biology into non-lipoprotein roles by placing it as a miRNA-controlled positive regulator of macrophage foam cell formation and of tumor cell signaling.\",\n      \"evidence\": \"Luciferase reporter validation of miR-1275/miR-4510 targeting plus APOC2 knockdown with ox-LDL uptake and AKT/ERK readouts in macrophages and GIST cells\",\n      \"pmids\": [\"31935511\", \"31975384\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether intracellular/autocrine APOC2 signals independently of its extracellular LPL-cofactor role unclear\", \"Direct receptor or effector linking APOC2 to AKT/ERK not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Resolved the molecular basis of LPL activation versus inhibition, showing APOC2 and ANGPTL4 bind overlapping LPL sites but exert opposite effects on enzyme stability.\",\n      \"evidence\": \"HDX-MS binding-site mapping of APOC2 and ANGPTL4 on LPL with thermal stability assays\",\n      \"pmids\": [\"37094117\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution co-structure of the APOC2\\u2013LPL complex\", \"How lid stabilization translates to increased catalysis kinetically not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected APOC2 to thermogenic adipose biology by placing it downstream of FXR and upstream of browning markers.\",\n      \"evidence\": \"FXR agonist/knockdown and APOC2 overexpression in beige adipocytes with UCP1/PGC1\\u03b1 readouts\",\n      \"pmids\": [\"39798876\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which APOC2 induces UCP1/PGC1\\u03b1 unknown\", \"Single lab, in vivo relevance to whole-body thermogenesis not established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Implicated APOC2 in cancer cell survival through JAK-STAT signaling in renal carcinoma.\",\n      \"evidence\": \"APOC2 knockdown in ccRCC cells with p-JAK1/2/STAT3 readout and STAT3 agonist rescue\",\n      \"pmids\": [\"41296440\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct link between APOC2 and JAK activation not defined\", \"Whether effect is cell-intrinsic or secretion-dependent unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How APOC2's canonical extracellular lipase-cofactor function mechanistically relates to its reported intracellular/signaling roles in macrophages, adipocytes, and tumor cells remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying mechanism links LPL activation to AKT/ERK and JAK-STAT signaling\", \"No structural model of the APOC2\\u2013LPL complex\", \"Receptors mediating non-lipolytic APOC2 effects unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 2, 4]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 2, 3]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"LPL\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}